Cardiff Oncology, Inc. Common Stock
CRDF Real Time Price USDRecent trades of CRDF by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CRDF's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
CRDF Revenue by Segment or Geography
New patents grants
-
Patent Title: Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer Apr. 01, 2025
-
Patent Title: Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer Nov. 19, 2024
-
Patent Title: Cancer treatment using fgfr inhibitors and plk1 inhibitors Apr. 16, 2024
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CRDF
Recent picks made for CRDF stock on CNBC
ETFs with the largest estimated holdings in CRDF
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CRDF stock a Buy, Sell, or Hold?
- What is the price target for $CRDF stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CRDF stock?
- Who owns the most shares of $CRDF stock?
- What funds own $CRDF stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CRDF Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.